Middle East respiratory syndrome coronavirus (MERS-CoV) is an emerging zoonotic pathogen with a broad host range. The extent of MERS-CoV in nature can be traced to its adaptable cell entry steps. The virus can bind host-cell carbohydrates as well as proteinaceous receptors. Following receptor interaction, the virus can utilize diverse host proteases for cleavage activation of virus-host cell membrane fusion and subsequent genome delivery. The fusion and genome delivery steps can be completed at variable times and places, either at or near cell surfaces or deep within endosomes. Investigators focusing on the CoVs have developed several methodologies that effectively distinguish these different cell entry pathways. Here we describe these methods, highlighting virus-cell entry factors, entry inhibitors, and viral determinants that specify the cell entry routes. While the specific methods described herein were utilized to reveal MERS-CoV entry pathways, they are equally suited for other CoVs, as well as other protease-dependent viral species.
Introduction
Middle East respiratory syndrome coronavirus (MERS-CoV) is endemic in bats, and also in dromedary camels, and can be transmitted zoonotically from camels to humans [1] [2] [3] [4] [5] [6] . The virus was discovered in humans in 2012, and since then there has been over 2,000 laboratory-confirmed cases worldwide, with 35% of infected humans suffering fatal outcomes [7] [8] [9] . Although MERS-CoV zoonotic and human-to-human transmission rates have declined due to general awareness and improved hospital practices, there are continued possibilities for epidemics, and there is a need for preventive vaccines and therapeutic antivirals. Mechanistic insights into human MERS-CoV entry will promote vaccine and antiviral drug developments.
MERS-CoV, like all other coronaviruses, exists as enveloped extracellular particles with protruding spike (S) proteins. Infection is initiated through viral S protein binding to host cell receptors.
Subsequent proteolytic cleavage of cell-bound S proteins triggers S protein-mediated coalescence (fusion) of viral and cell membranes. The triggering process involves a series of currently obscure S protein conformational changes, from "pre-fusion" metastable states to "extended fusion intermediates" to "post-fusion" collapsed states that exist after virus and cell membranes have coalesced and viral mRNA genomes have dispensed into the host cell cytoplasm [10, 11] . These events depend on cellular proteases, and as one may expect, the availability of particular proteases immediately following receptor engagement is a rate-limiting step in CoV entry.
Cellular proteases accumulate in distinct subcellular locations on the endocytic CoV entry pathway: serine proteases such as trypsin and elastase are extracellular; the type II transmembrane serine proteases (TTSPs) are anchored into plasma membranes; and the cysteine-type cathepsin proteases are enriched in endosomes [12, 13] . For several CoV infections, not all of these proteases are required; however, it is possible that each has distinct potential to activate fusion such that a productive infection ensues. There is evidence that particular CoVs have "preferred" in vivo entry routes (e.g., MERS-CoV and 229E-CoV prefer plasma membrane entry, while some MHV-CoVs prefer endosome entry [14-19], (see Fig. 1 ). Knowledge of these preferred routes, and their relation to virus-induced disease, is necessary to identify virus variants that might have high transmissibility and disease potential, and to recognize the host factors that might be targeted therapeutically such that infections are suppressed at the cell entry stage.
Here we provide protocols to dissect CoV entry pathways. These include procedures for pseudovirus production, particle purification and concentration, as well as specific assays to differentiate CoV entry pathways. While the protocols are set for characterizing MERS-CoV entry, they can be readily adjusted to evaluate other CoV and other protease-dependent virus entry events. 7. Expression plasmids for: hTMPRSS2, hCD9, hIFITM3.
Materials

Particle Production
Methods
Carry out all incubations at 37 C with 5% CO 2 unless otherwise specified.
VSV-Based Pseudovirus
Production (see Note 1)
1. Plate enough 293T cells (5 Â 10 6 ) in 20 ml into a 15 cm dish to reach 80% confluency on the next day.
2. On the following day, make transfection mixture by adding 20 μg of MERS-CoV-spike plasmid (see Note 2) and 110 μl of PEI into 2 ml of OptiMEM. Incubate the mixture in the dark for 15 min at room temperature.
3. Replace existing media with 20 ml of transfection media (pre-warmed to 37 C, see Note 3). Add transfection mixture dropwise onto the cells. Incubate the cells for 6-8 h (see Note 4).
4.
Replace transfection media with 20 ml of 293T cell media and incubate overnight.
5. Dilute 100Â transducing particle (VSVΔG-Fluc pseudotyped with Junin virus (JUNV) GP, see Note 5) into 15 ml of pre-warmed serum-free media, which is then used to replace existing media on the transfected cells. Incubate cells for 2 h. 9. Transfer supernatant into a fresh tube and freeze it at À80 C.
10. On the following day, repeat steps 6-9 (second collection).
11. On the final day, collect supernatant (third collection), discard cells, repeat steps 7-9.
Particle Purification and Concentration
We noted that pseudoviruses lose their transduction capabilities (up to 90%!) upon exposure to the high g-forces (~100,000 Â g) commonly used in traditional viral concentration methods. Therefore, we adopted a low-speed viral concentration and purification protocol that achieves viral concentration without compromising viral transduction capabilities. 5. After the spin, carefully take out the Ultra-Clear tube, and remove all the supernatant without disturbing the pellet at the bottom center (may be invisible). Quickly add back 350 ml of serum-free media, and gently resuspend the pellet with a 1 ml pipette (see Note 8) . Aliquot and store the fully resuspended sample (now 100Â and purified) at À80 C for future use.
Characterizing CoV Entry Pathways
Subsequent to receptor engagement, CoV spikes require proteolytic cleavage to trigger membrane fusion. Two classes of cellular proteases have been identified to trigger CoV fusions: Serine proteases that are either secreted or expressed on the plasma membrane [14, 17] , and cysteine proteases that resides in the endosome [18, 19] . Therefore, the utilization of specific proteases by a given CoV also dictates its site of entry. We utilize several assays to differentiate the preferred site of entry for wild-type (WT) and mutant MERS spikes, the efficacies of entry inhibitors, and the identification of pro-or antiviral host factors.
Characterizing CoV Entry Kinetics Using Protease Inhibitor Cocktails (see Note 9)
The CoV site of entry is correlated with entry kinetics, with viral entry at the plasma membrane being "early," and entry through endosomes "late," in relation to the different virus trafficking times prior to membrane fusion [15] [16] [17] . Together with the knowledge that CoV entry requires proteolysis, we utilize a time-course assay to characterize CoV entry kinetics, where protease inhibitors are added at various time points to arrest future entry, allowing readouts for infection within short inoculation time windows. The entry assay (Subheading 3.4.1) can sensitively distinguish viruses with accelerated or delayed kinetics, but it is frequently time and reagent consuming. The assay can be simplified by an alternative where titration of a particular inhibitor is applied for a short period of time. 
5.
Remove media, add 50 μl of 1ÂCCLR to lyse cells. Freeze the plate at À80 C for 30 min. Thaw the plate and transfer 20 μl to a white reading plate to analyze firefly luciferase activity. Normalize enzyme activity from all conditions to the vehicle control, which is set to "100%." Plot data as "% viral entry."
Characterizing Entry Routes Using Spike Fusion Antagonists
The protocol described in Subheading 3.4.2 is flexible and can be tailored to evaluate different viral inhibitors. These include fusion inhibitors. CoV spike proteins facilitate membrane fusion by transiting from "extended fusion intermediates" to "post-fusion" conformations. This transition requires interactions between antiparallel helices termed heptad repeat region 1 (HR1) and 2 (HR2) [20, 21] , and can be arrested by exogenous HR2 peptides, which bind to the fusion intermediates. Typically, HR2 peptides do not enter endosomes and therefore only arrest viruses that transition into intermediate conformations extracellularly, i.e., at target cell plasma membranes. However, lipid-conjugated HR2 peptides can bind plasma membranes and endocytose, accumulating in endosomes such that they will arrest intracellular virus-cell membrane fusion. Using a modified Subheading 3.4.2, we tested the efficacy of native vs. lipid-conjugated HR2 on blocking CoV endosomal entry [22] . 7. At the indicated spin speed, the k-factor is 4556. Since the sedimentation coefficients of VSV [25] or HIV [26] pseudovirus are around 500, a 9-h spin is sufficient. The actual spin time is doubled to insure that the pseudoviruses are pelleted through the more viscous 20% sucrose cushion. 13. Samples can be kept at À80 C for up to a month before reading Fluc. To further prevent signal loss, protease inhibitor cocktail can be added to 1x CCLR before use.
14. For cell types that are killed by PEI:DNA transfection, lipidbased transfection vectors such as lipofectamine can be used instead. For cell types that are resistant to transfection, retro-or lenti-viral-based or adenovirus-based transduction systems can be used to introduce genes of interest [15] .
